No RAD140 dosage is approved for any purpose, and the reason is simple: the compound has been through one dose-finding trial, the kind that raises the amount in steps until adverse events limit it, and nothing beyond. That RAD 140 study administered 50, 100 or 150 mg once daily to women with advanced breast cancer, with no fixed course length.
What those amounts did is on record. The commonest adverse events, harms recorded during administration whatever their cause, were raised liver enzymes, the aspartate and alanine aminotransferases released from injured liver tissue, and a later study of vosilasarm, RAD140’s drug name, still recorded raised liver tests at 10 mg twice daily. Published case reports, single-patient accounts in the medical literature, describe drug-induced liver injury after weeks to months of exposure. The lower daily amounts described outside the trials have never been tested at all.
Where did the figures come from? RAD140 is an oral nonsteroidal selective androgen receptor modulator (SARM) acting on the androgen receptor inside cells, and that RAD 140 mechanism of action carried it into development as a drug candidate in breast cancer, so every RAD 140 dose in the research comes from those cancer trials and from animal studies dosed in mg/kg, milligrams per kilogram of body weight. Testolone has no marketing authorisation anywhere, and the published cases state that the US Food and Drug Administration (FDA) has not approved it.
This article keeps three tiers apart, because they answer the question to different depths: the amounts and lengths of exposure recorded in the trials, in the published cases and in the animal studies, and beside them the amounts described outside the trials, so that a tested amount is never read as a described one. Recovery after exposure, combinations with other compounds, RAD150 and legal detail beyond approval and sport status have their own pages.
What doses and how many weeks were used in the phase 1 trial?
RAD140 dose levels in the human trials
Trial arm
Population
Amount administered
Patients
What was recorded
Phase 1, first level
Postmenopausal women with ER+/HER2- metastatic breast cancer
Advanced or metastatic AR+/ER+/HER2- breast cancer
10 mg twice daily
Not given in the abstract
Raised liver tests, no rate given
Liver tests, SHBG and PSA at the trial doses
The trial’s adverse-event table pooled all three dose levels, and raised liver enzymes dominated it. Among the treatment-emergent adverse events, those arising during administration whatever their cause, aspartate aminotransferase (AST) was high in most patients and alanine aminotransferase (ALT) in nearly half, total bilirubin up in rather more than a quarter, at the rates charted here; vomiting, dehydration, decreased appetite and decreased weight each matched the bilirubin rate. Severity followed the same markers: adverse events of grade 3 or 4 (severe and life-threatening) occurred in 16 of 22 patients (72.7%), at those grades rises in AST and ALT each occurred in 22.7% of the women, as did hypophosphataemia, a fall below normal in the blood’s phosphate concentration, and treatment-related adverse events occurred in 17 of 22 patients (77.3%), 7 at grade 3 and none at grade 4.
Pooled across all 22, these rates cannot show how the liver signal scaled with the amount administered, and that pooling is the limit this article runs into again and again.
[Figure 1. Adverse events in RAD140’s phase 1 trial. Share of the 22 women with advanced breast cancer who had each adverse event at any grade, whatever the cause, with the daily doses of 50 to 150 mg pooled. The liver enzymes AST and ALT stand clear of the rest.]
The trial counted rather than measured its two androgen-dependent markers. Sex hormone-binding globulin (SHBG) fell in 18 of 18 patients assessed; prostate-specific antigen (PSA) rose in 16 of 20, so four showed no rise, and the two markers did not track each other from one woman to the next. Neither was broken down by dose level. Backed by paired tumour biopsies, the counts established that RAD-140 engaged the androgen receptor, not how that engagement varied with the dose, and on these data the authors judged the safety profile acceptable in patients with advanced cancer.
Half-life and the once-daily schedule in the trial
The RAD 140 half-life measured in the trial, the elimination half-life over which the plasma concentration falls by half, was 44.7 hours, and on that figure the compound was administered once a day. Because the interval between administrations was shorter than the half-life, the plasma concentration climbed over the first days towards a steady state instead of returning to baseline each day; that accumulation, characterised in the pharmacokinetic expansion cohort, is what made a single daily administration sufficient for the trial’s purposes.
The half-life (t 1/2 ) of 44.7 hours supported QD dosing.
RAD140 came back to patients under the name vosilasarm (EP0062), in a phase 1/2 trial, a design that joins the first stage of human testing to an early test of effect, in advanced or metastatic breast cancer. The disease was AR+/ER+/HER2- breast cancer, positive for the androgen and oestrogen receptors and negative for HER2, and the metastatic cases fell within ER+/HER2- metastatic breast cancer, spread disease that is oestrogen-receptor-positive and HER2-negative. That trial administered RAD 140 10 mg twice daily, and at that strength it recorded raised liver function tests.
Twice daily at that strength means RAD140 at 20mg a day, well below the 50 mg that opened the first-in-human escalation. The record, though, is a conference abstract: it gives the amount and the liver finding, and neither a rate, nor a count of patients at that level, nor a length of exposure.
What daily dose do users run, such as 5, 10 or 20 mg?
Outside the published trials, the daily dose of RAD 140 is described most often as a single fixed amount in mg administered once a day, at the low end of the range in question and far below anything the trials administered; how much RAD 140 is named for women is given as lower than the amount named for men, a difference that recurs widely.
In those accounts an increase partway through exposure also appears: a step up from a low starting figure after the first weeks, with the higher amount sometimes split between a morning and an evening administration. A few call the higher amounts very large for this compound or too little gain for their size. One figure held from start to finish remains the arrangement described most widely, and graded increases are the usual variation on it.
Beyond the trial data, RAD140 is described in comparisons with other selective androgen receptor modulators as the more potent member of a pair, administered at a smaller amount; those comparisons belong to the wider RAD 140 experience reported outside the trials, where each amount is paired with its effects.
Is 5 mg nearly as effective as 20–30 mg?
Outside the published trials, low daily amounts of RAD140 several times smaller than the higher ones in question are described as nearly as effective as those higher amounts, with considerably fewer adverse effects; the share of the effect said to survive at the low amount runs from most of it to nearly all of it, and the claim is sometimes turned round, so that the higher amounts are said to add little while multiplying the adverse effects.
Accounts outside the published studies describe the low amount as sufficient for a first period of exposure and as unlikely to do harm, and the higher amounts as bringing a greater increase in muscle strength with more adverse effects alongside. Several of them ask whether the low amount has ever been held for a whole period of exposure rather than raised, a question that suggests the claim circulates more widely than the observations that would test it, and a few ask whether a second period of exposure produces a smaller effect than the first.
Is 10 mg enough, or is 20 mg better?
In descriptions beyond the trials, the lower of the two daily figures is where exposure starts, and a step up to the higher follows only once the first weeks have passed without adverse effects. A return to the lower figure after that step is described too, as is the view that the higher one is far too large for this compound; the arrangement favoured for a first period of exposure holds the lower figure throughout, with a rise only near the end, if at all, and movement between the two partway through runs in both directions.
Do side effects get worse at 20 mg or 30 mg than at 10 mg?
Outside the published trials, adverse effects are described as more frequent and more marked at the higher amounts than at the lower one: few complaints at the lower amount, while complaints at the higher amounts prompt a reduction in the amount or an early end to exposure, and the middle figures are given as the point past which no further effect follows.
Selective androgen receptor modulators are generally held to produce adverse effects that depend on dose, so higher amounts are commonly described as bringing more frequent and more marked effects than lower ones. Rising exposure is linked most often to suppression of endogenous testosterone, to a fall in high-density lipoprotein cholesterol and to raised liver enzymes, with drug-induced liver injury at the serious end. The usual qualification is that the dose-response relationship in humans is poorly characterised: controlled human data are limited, and the published cases often involve material of uncertain purity or more than one compound.
How much does RAD140 suppress testosterone at 10 mg and at higher doses?
Outside the published trials, RAD140 is widely described as suppressing endogenous testosterone even at the lowest amounts commonly named, and more strongly at the higher ones; the suppression is treated as a near-certainty of exposure rather than a risk, and the arrangements described are built around that expectation.
In those accounts a SERM such as enclomiphene (the trans isomer of clomifene, used to raise gonadotrophin output) is added during or after a period of exposure. SERMs (selective oestrogen receptor modulators) are a drug class acting on the oestrogen receptor, as agonist in some tissues and antagonist in others, and that receptor is what sets SARMs and SERMs apart; of all the agents named alongside RAD140, SERMs come up most often.
Outside the trial record, tamoxifen is described as doing little against suppression in one account and as helping in others, and RAD 140 blood work is described as the way to judge the degree of suppression, sometimes before exposure and sometimes partway through; in those arrangements the SERM is as fixed a part of the picture as the compound itself.
How long does a typical RAD140 cycle last?
Beyond the trial data, a typical period of exposure to RAD140 is described as several weeks at one fixed daily amount, with longer periods running to a few months described less often; within those several weeks a lower amount over the first weeks before a rise is common, as is an end point fixed before exposure begins.
In those accounts an early end is also described, after adverse effects appear or after a blood test, yet the length is settled in advance far more often than it is judged as exposure proceeds. The trials themselves set no fixed course length, the phase 1 trial included.
Is a 4 or 6 week cycle long enough compared with 8 weeks?
Among the effects described outside the trials, the shorter periods of exposure raise the question of whether they run long enough for a change to be noticed, while the longer period is given far more often as the usual one, so the shorter periods are measured against it; stopping partway through such a period after complaints is described as well, along with the question of whether a shortened period counts at all.
Can RAD140 be taken every other day instead of daily?
RAD140 is described, outside the published trials, as administered once daily in most accounts, and RAD 140 every other day less often, usually with a larger single amount on the days it is given; the alternate-day arrangement is put forward not as equivalent to daily administration but as a way of spreading the same total amount.
In those accounts the spacing is reasoned from the compound’s long elimination half-life, though the figures cited for it outside the trials do not match the value measured in the trial, and the opposite position, that administration has to be daily, is stated just as plainly. Whether a split or an alternate schedule changes the complaints noticed recurs as a question, as does the bare choice between the two schedules.
Liver tests at the low and the high trial doses
The first-in-human phase 1 trial was recently published and did report a significant proportion of elevated aspartate aminotransferase, alanine transaminase, and total bilirubin among the test subjects.
At 50 to 150 mg a day in the phase 1 trial, raised AST and ALT were the two commonest adverse events, at the pooled rates of the liver-test section. The vosilasarm study administered a fraction of those daily amounts and still recorded raised liver tests at 10 mg twice daily, without a rate for them; the lower amount did not remove the liver signal in these patients, though the two studies differ in population and in reporting.
Neither study reports its adverse events by dose level, and the published cases add nothing on amount, since none records the amount administered each day. What they add is a pattern: the LiverTox class summary links selective androgen receptor modulators with cholestatic liver injury, the form it took in them. Liver tests are therefore the place where a signal by amount would have to be read, across both tiers of clinical evidence, and the published record does not settle whether such a signal exists.
The published cases tie liver injury to weeks or months of exposure, never to an amount, and its course and recovery are set out under RAD140 liver toxicity.
How do you measure a dose in ml from a liquid?
A dose of RAD140 in millilitres is measured from RAD-140 liquid by dividing the milligrams required by the concentration (mg per ml), the quantity of compound dissolved in each millilitre of solution. Among the effects described outside the trials, each is tied to a figure in milligrams, so the same division gives the volume in millilitres that holds it; research solutions are labelled by concentration while an experiment is specified in milligrams, and for any given label the conversion answers exactly how many ml of RAD 140 per day the specified quantity occupies. The same division serves every strength, so no worked example is needed.
Read the concentration Take the concentration in milligrams per millilitre from the label and the batch certificate, preferring the measured content where the certificate gives one.
Set the amount the experiment needs Note the amount of compound in milligrams that the experiment calls for, before handling the solution.
Divide amount by concentration Divide that amount by the concentration in milligrams per millilitre; the result is the volume in millilitres.
Measure the volume Draw the volume with a syringe of suitable range or a graduated pipette, a pipette marked with a volume scale, and read it at eye level on a millilitre scale.
Record the batch and the volume Log the batch number, concentration and volume drawn, so each measurement traces back to its certificate.
A printed strength can differ from the content, as a regulator’s tests of SARM products showed, so a quantity described outside the trials cannot be read as what was administered; for laboratory material the gap is closed by a SARM certificate of analysis.
In those accounts the same gap stands behind every compound, and each one in our SARMs for sale UK listing carries the same certificate.
Doses in the mouse, rat and horse studies
One amount dominates the animal work: 5 mg/kg a day. Mice aged 23 months given it for 6 weeks had a 10.4% higher ejection fraction, with stroke volume up by 9.6 µL and cardiac output by 4.5 mL/min, and myocardial strain and relaxation times improved in males more than in females. At the same amount and length a second study found that male mice preserved lean mass and bone mineral density with no change in the frailty index, and that females gained neither.
Longer exposure in younger animals went the other way: young and adult female mice administered 5 mg/kg for 10 weeks had a higher frailty index and a higher mortality risk than controls, with no gain in strength. In horses the amounts were smaller and the purpose analytical, 0.3 mg/kg daily for 3 days in a hair-detection study, while an earlier metabolism study in three retired geldings states no amount at all. The founding preclinical report characterised RAD140 as potent and orally bioavailable in rats and monkeys, with a binding constant (Ki) of 7 nM against 29 nM for the comparator. All these amounts are scaled to body weight, and the records offer no conversion to a human figure.
Limits of the dose evidence on RAD140
The human evidence on dose rests on one published phase 1 trial in 22 heavily pretreated postmenopausal women with metastatic breast cancer, whose adverse-event rates are pooled across three levels and so cannot show how harm scaled with the quantity administered. The vosilasarm finding rests on a conference abstract that gives a figure and a liver signal without rates or a length of exposure, and each published case of drug-induced liver injury describes a single patient without a daily figure.
The animal studies scaled their amounts to body weight and ran for weeks, offering no conversion to a human figure. Regulator testing found products sold as SARMs significantly under-dosed, and urine sampled outside sport often held several such compounds at once, so an amount described outside a trial cannot be read as that amount of RAD140 alone. The RAD-140 for sale with us is supplied for laboratory research with batch and purity data.
Six matters in this article rest on descriptions outside the published trials alone, and no published study among this article’s sources has measured them:
the daily amounts described
the claim that a low amount is nearly as effective as a high one
complaints by amount
suppression of endogenous testosterone at the lowest amounts
the lengths of exposure
alternate-day administration
No regulator has set an amount, a schedule or a length of exposure for RAD140, which has a status in anti-doping and none in therapeutics.
Frequently asked questions
Can RAD140 be taken every other day?
The clinical trials administered RAD140 once daily, on the strength of a measured elimination half-life long enough to keep the plasma concentration raised between administrations. Outside the trial record, alternate-day administration is a minority arrangement reasoned from that same long half-life, usually with a larger single amount on the days it is given, and no study has ever compared the two schedules.
What dose should a first cycle use?
No regulator has set a starting figure for RAD140, and no study has tested one. Outside the published trials, a first period of exposure is described as using the lowest amounts in common currency, with no other compounds alongside and a rise, if any, only later; the trial amounts were far higher and went to patients with advanced cancer.
Important information. This article summarises published research and case reports, and notes where effects are described outside the published trials. It is not medical advice, and Max Muscle Labs does not give dosing guidance or any information implying human use. Many of the compounds discussed here are not approved for human use by the MHRA, the FDA or any other regulator, and many are prohibited in sport by WADA. Products sold by Max Muscle Labs are supplied strictly for laboratory and analytical research use and are not for human or veterinary consumption.
Check what you remember
4 questions on this article; the right answer is marked.
Which adverse events were the most common in the first-in-human RAD140 trial?
Raised liver enzymes, AST and ALT ✓
Falls in HDL cholesterol levels
Low phosphate levels in the blood
Suppressed endogenous testosterone levels
Raised AST (59.1%) and raised ALT (45.5%) led the trial's adverse events, ahead of low phosphate and every other finding.
What do the published RAD140 liver injury case reports tie the injury to?
Weeks to months of exposure, no amount given ✓
A stated amount above the trial's top level
A stated amount far below the trial's levels
Contaminants found in each product the patients used
The cases date the injury to exposures of 5 to 16 weeks or a few months, and none of them records the amount used each day.
What did 10 weeks of RAD140 do in young and adult female mice?
Higher frailty and mortality, no gain in strength ✓
Higher strength and lean mass, with less frailty overall
Preserved lean mass and bone mineral density
Improved ejection fraction and cardiac output
After 10 weeks the treated females were frailer and had a higher mortality risk than controls, with no gain in strength.
What did Australia's TGA find when it tested unapproved products sold as SARMs?
Much less of the named compound than labelled ✓
Much more of the named compound than labelled
The labelled amount within normal tolerance
Anabolic steroids in place of the named compound
The regulator found these products held significantly less of the named compound than declared, so the printed amount may not be the amount present.
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
No published study has tested PCT for RAD 140, and a case report records suppressed testosterone normalising once supplements containing it were stopped.
Hurry while stocks last! Use code PAYDAY15 at checkout to get 15% off sitewide. Valid for
Join the WaitlistWe will inform you when the product is back in stock. Enter your email address below.
RAD140 dose: what the trials gave and the evidence covers
By Ailsa Gemmell · Reviewed by Elizabeth Hyams
Published · Updated · 18 min read
RAD140 doses in the research, in brief
No RAD140 dosage is approved for any purpose, and the reason is simple: the compound has been through one dose-finding trial, the kind that raises the amount in steps until adverse events limit it, and nothing beyond. That RAD 140 study administered 50, 100 or 150 mg once daily to women with advanced breast cancer, with no fixed course length.
What those amounts did is on record. The commonest adverse events, harms recorded during administration whatever their cause, were raised liver enzymes, the aspartate and alanine aminotransferases released from injured liver tissue, and a later study of vosilasarm, RAD140’s drug name, still recorded raised liver tests at 10 mg twice daily. Published case reports, single-patient accounts in the medical literature, describe drug-induced liver injury after weeks to months of exposure. The lower daily amounts described outside the trials have never been tested at all.
Where did the figures come from? RAD140 is an oral nonsteroidal selective androgen receptor modulator (SARM) acting on the androgen receptor inside cells, and that RAD 140 mechanism of action carried it into development as a drug candidate in breast cancer, so every RAD 140 dose in the research comes from those cancer trials and from animal studies dosed in mg/kg, milligrams per kilogram of body weight. Testolone has no marketing authorisation anywhere, and the published cases state that the US Food and Drug Administration (FDA) has not approved it.
This article keeps three tiers apart, because they answer the question to different depths: the amounts and lengths of exposure recorded in the trials, in the published cases and in the animal studies, and beside them the amounts described outside the trials, so that a tested amount is never read as a described one. Recovery after exposure, combinations with other compounds, RAD150 and legal detail beyond approval and sport status have their own pages.
What doses and how many weeks were used in the phase 1 trial?
RAD140 dose levels in the human trials
Liver tests, SHBG and PSA at the trial doses
The trial’s adverse-event table pooled all three dose levels, and raised liver enzymes dominated it. Among the treatment-emergent adverse events, those arising during administration whatever their cause, aspartate aminotransferase (AST) was high in most patients and alanine aminotransferase (ALT) in nearly half, total bilirubin up in rather more than a quarter, at the rates charted here; vomiting, dehydration, decreased appetite and decreased weight each matched the bilirubin rate. Severity followed the same markers: adverse events of grade 3 or 4 (severe and life-threatening) occurred in 16 of 22 patients (72.7%), at those grades rises in AST and ALT each occurred in 22.7% of the women, as did hypophosphataemia, a fall below normal in the blood’s phosphate concentration, and treatment-related adverse events occurred in 17 of 22 patients (77.3%), 7 at grade 3 and none at grade 4.
Pooled across all 22, these rates cannot show how the liver signal scaled with the amount administered, and that pooling is the limit this article runs into again and again.
The trial counted rather than measured its two androgen-dependent markers. Sex hormone-binding globulin (SHBG) fell in 18 of 18 patients assessed; prostate-specific antigen (PSA) rose in 16 of 20, so four showed no rise, and the two markers did not track each other from one woman to the next. Neither was broken down by dose level. Backed by paired tumour biopsies, the counts established that RAD-140 engaged the androgen receptor, not how that engagement varied with the dose, and on these data the authors judged the safety profile acceptable in patients with advanced cancer.
Half-life and the once-daily schedule in the trial
The RAD 140 half-life measured in the trial, the elimination half-life over which the plasma concentration falls by half, was 44.7 hours, and on that figure the compound was administered once a day. Because the interval between administrations was shorter than the half-life, the plasma concentration climbed over the first days towards a steady state instead of returning to baseline each day; that accumulation, characterised in the pharmacokinetic expansion cohort, is what made a single daily administration sufficient for the trial’s purposes.
Vosilasarm at a lower dose in breast cancer
RAD140 came back to patients under the name vosilasarm (EP0062), in a phase 1/2 trial, a design that joins the first stage of human testing to an early test of effect, in advanced or metastatic breast cancer. The disease was AR+/ER+/HER2- breast cancer, positive for the androgen and oestrogen receptors and negative for HER2, and the metastatic cases fell within ER+/HER2- metastatic breast cancer, spread disease that is oestrogen-receptor-positive and HER2-negative. That trial administered RAD 140 10 mg twice daily, and at that strength it recorded raised liver function tests.
Twice daily at that strength means RAD140 at 20mg a day, well below the 50 mg that opened the first-in-human escalation. The record, though, is a conference abstract: it gives the amount and the liver finding, and neither a rate, nor a count of patients at that level, nor a length of exposure.
What daily dose do users run, such as 5, 10 or 20 mg?
Outside the published trials, the daily dose of RAD 140 is described most often as a single fixed amount in mg administered once a day, at the low end of the range in question and far below anything the trials administered; how much RAD 140 is named for women is given as lower than the amount named for men, a difference that recurs widely.
In those accounts an increase partway through exposure also appears: a step up from a low starting figure after the first weeks, with the higher amount sometimes split between a morning and an evening administration. A few call the higher amounts very large for this compound or too little gain for their size. One figure held from start to finish remains the arrangement described most widely, and graded increases are the usual variation on it.
Beyond the trial data, RAD140 is described in comparisons with other selective androgen receptor modulators as the more potent member of a pair, administered at a smaller amount; those comparisons belong to the wider RAD 140 experience reported outside the trials, where each amount is paired with its effects.
Is 5 mg nearly as effective as 20–30 mg?
Outside the published trials, low daily amounts of RAD140 several times smaller than the higher ones in question are described as nearly as effective as those higher amounts, with considerably fewer adverse effects; the share of the effect said to survive at the low amount runs from most of it to nearly all of it, and the claim is sometimes turned round, so that the higher amounts are said to add little while multiplying the adverse effects.
Accounts outside the published studies describe the low amount as sufficient for a first period of exposure and as unlikely to do harm, and the higher amounts as bringing a greater increase in muscle strength with more adverse effects alongside. Several of them ask whether the low amount has ever been held for a whole period of exposure rather than raised, a question that suggests the claim circulates more widely than the observations that would test it, and a few ask whether a second period of exposure produces a smaller effect than the first.
Is 10 mg enough, or is 20 mg better?
In descriptions beyond the trials, the lower of the two daily figures is where exposure starts, and a step up to the higher follows only once the first weeks have passed without adverse effects. A return to the lower figure after that step is described too, as is the view that the higher one is far too large for this compound; the arrangement favoured for a first period of exposure holds the lower figure throughout, with a rise only near the end, if at all, and movement between the two partway through runs in both directions.
Do side effects get worse at 20 mg or 30 mg than at 10 mg?
Outside the published trials, adverse effects are described as more frequent and more marked at the higher amounts than at the lower one: few complaints at the lower amount, while complaints at the higher amounts prompt a reduction in the amount or an early end to exposure, and the middle figures are given as the point past which no further effect follows.
Selective androgen receptor modulators are generally held to produce adverse effects that depend on dose, so higher amounts are commonly described as bringing more frequent and more marked effects than lower ones. Rising exposure is linked most often to suppression of endogenous testosterone, to a fall in high-density lipoprotein cholesterol and to raised liver enzymes, with drug-induced liver injury at the serious end. The usual qualification is that the dose-response relationship in humans is poorly characterised: controlled human data are limited, and the published cases often involve material of uncertain purity or more than one compound.
How much does RAD140 suppress testosterone at 10 mg and at higher doses?
Outside the published trials, RAD140 is widely described as suppressing endogenous testosterone even at the lowest amounts commonly named, and more strongly at the higher ones; the suppression is treated as a near-certainty of exposure rather than a risk, and the arrangements described are built around that expectation.
In those accounts a SERM such as enclomiphene (the trans isomer of clomifene, used to raise gonadotrophin output) is added during or after a period of exposure. SERMs (selective oestrogen receptor modulators) are a drug class acting on the oestrogen receptor, as agonist in some tissues and antagonist in others, and that receptor is what sets SARMs and SERMs apart; of all the agents named alongside RAD140, SERMs come up most often.
Outside the trial record, tamoxifen is described as doing little against suppression in one account and as helping in others, and RAD 140 blood work is described as the way to judge the degree of suppression, sometimes before exposure and sometimes partway through; in those arrangements the SERM is as fixed a part of the picture as the compound itself.
How long does a typical RAD140 cycle last?
Beyond the trial data, a typical period of exposure to RAD140 is described as several weeks at one fixed daily amount, with longer periods running to a few months described less often; within those several weeks a lower amount over the first weeks before a rise is common, as is an end point fixed before exposure begins.
In those accounts an early end is also described, after adverse effects appear or after a blood test, yet the length is settled in advance far more often than it is judged as exposure proceeds. The trials themselves set no fixed course length, the phase 1 trial included.
Is a 4 or 6 week cycle long enough compared with 8 weeks?
Among the effects described outside the trials, the shorter periods of exposure raise the question of whether they run long enough for a change to be noticed, while the longer period is given far more often as the usual one, so the shorter periods are measured against it; stopping partway through such a period after complaints is described as well, along with the question of whether a shortened period counts at all.
Can RAD140 be taken every other day instead of daily?
RAD140 is described, outside the published trials, as administered once daily in most accounts, and RAD 140 every other day less often, usually with a larger single amount on the days it is given; the alternate-day arrangement is put forward not as equivalent to daily administration but as a way of spreading the same total amount.
In those accounts the spacing is reasoned from the compound’s long elimination half-life, though the figures cited for it outside the trials do not match the value measured in the trial, and the opposite position, that administration has to be daily, is stated just as plainly. Whether a split or an alternate schedule changes the complaints noticed recurs as a question, as does the bare choice between the two schedules.
Liver tests at the low and the high trial doses
At 50 to 150 mg a day in the phase 1 trial, raised AST and ALT were the two commonest adverse events, at the pooled rates of the liver-test section. The vosilasarm study administered a fraction of those daily amounts and still recorded raised liver tests at 10 mg twice daily, without a rate for them; the lower amount did not remove the liver signal in these patients, though the two studies differ in population and in reporting.
Neither study reports its adverse events by dose level, and the published cases add nothing on amount, since none records the amount administered each day. What they add is a pattern: the LiverTox class summary links selective androgen receptor modulators with cholestatic liver injury, the form it took in them. Liver tests are therefore the place where a signal by amount would have to be read, across both tiers of clinical evidence, and the published record does not settle whether such a signal exists.
The published cases tie liver injury to weeks or months of exposure, never to an amount, and its course and recovery are set out under RAD140 liver toxicity.
How do you measure a dose in ml from a liquid?
A dose of RAD140 in millilitres is measured from RAD-140 liquid by dividing the milligrams required by the concentration (mg per ml), the quantity of compound dissolved in each millilitre of solution. Among the effects described outside the trials, each is tied to a figure in milligrams, so the same division gives the volume in millilitres that holds it; research solutions are labelled by concentration while an experiment is specified in milligrams, and for any given label the conversion answers exactly how many ml of RAD 140 per day the specified quantity occupies. The same division serves every strength, so no worked example is needed.
A printed strength can differ from the content, as a regulator’s tests of SARM products showed, so a quantity described outside the trials cannot be read as what was administered; for laboratory material the gap is closed by a SARM certificate of analysis.
In those accounts the same gap stands behind every compound, and each one in our SARMs for sale UK listing carries the same certificate.
Doses in the mouse, rat and horse studies
One amount dominates the animal work: 5 mg/kg a day. Mice aged 23 months given it for 6 weeks had a 10.4% higher ejection fraction, with stroke volume up by 9.6 µL and cardiac output by 4.5 mL/min, and myocardial strain and relaxation times improved in males more than in females. At the same amount and length a second study found that male mice preserved lean mass and bone mineral density with no change in the frailty index, and that females gained neither.
Longer exposure in younger animals went the other way: young and adult female mice administered 5 mg/kg for 10 weeks had a higher frailty index and a higher mortality risk than controls, with no gain in strength. In horses the amounts were smaller and the purpose analytical, 0.3 mg/kg daily for 3 days in a hair-detection study, while an earlier metabolism study in three retired geldings states no amount at all. The founding preclinical report characterised RAD140 as potent and orally bioavailable in rats and monkeys, with a binding constant (Ki) of 7 nM against 29 nM for the comparator. All these amounts are scaled to body weight, and the records offer no conversion to a human figure.
Limits of the dose evidence on RAD140
The human evidence on dose rests on one published phase 1 trial in 22 heavily pretreated postmenopausal women with metastatic breast cancer, whose adverse-event rates are pooled across three levels and so cannot show how harm scaled with the quantity administered. The vosilasarm finding rests on a conference abstract that gives a figure and a liver signal without rates or a length of exposure, and each published case of drug-induced liver injury describes a single patient without a daily figure.
The animal studies scaled their amounts to body weight and ran for weeks, offering no conversion to a human figure. Regulator testing found products sold as SARMs significantly under-dosed, and urine sampled outside sport often held several such compounds at once, so an amount described outside a trial cannot be read as that amount of RAD140 alone. The RAD-140 for sale with us is supplied for laboratory research with batch and purity data.
Six matters in this article rest on descriptions outside the published trials alone, and no published study among this article’s sources has measured them:
No regulator has set an amount, a schedule or a length of exposure for RAD140, which has a status in anti-doping and none in therapeutics.
Frequently asked questions
Can RAD140 be taken every other day?
The clinical trials administered RAD140 once daily, on the strength of a measured elimination half-life long enough to keep the plasma concentration raised between administrations. Outside the trial record, alternate-day administration is a minority arrangement reasoned from that same long half-life, usually with a larger single amount on the days it is given, and no study has ever compared the two schedules.
What dose should a first cycle use?
No regulator has set a starting figure for RAD140, and no study has tested one. Outside the published trials, a first period of exposure is described as using the lowest amounts in common currency, with no other compounds alongside and a rise, if any, only later; the trial amounts were far higher and went to patients with advanced cancer.
Check what you remember
4 questions on this article; the right answer is marked.
Raised AST (59.1%) and raised ALT (45.5%) led the trial's adverse events, ahead of low phosphate and every other finding.
The cases date the injury to exposures of 5 to 16 weeks or a few months, and none of them records the amount used each day.
After 10 weeks the treated females were frailer and had a higher mortality risk than controls, with no gain in strength.
The regulator found these products held significantly less of the named compound than declared, so the printed amount may not be the amount present.
Ailsa Gemmell · NHS Greater Glasgow and Clyde
Specialty Registrar in Gastroenterology
Ailsa Gemmell is a specialty registrar in gastroenterology at NHS Greater Glasgow and Clyde. Ailsa specialises in hepatology and liver safety.
Elizabeth Hyams · Imperial College London · Last reviewed
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
Related Posts
Ostarine course length: trial durations and what is reported
ostarine cycle length in the enobosarm trials ran 86 to 147 days once daily, while published liver injury cases followed about six weeks of exposure.
RAD 140 half life: the trial figure, timing and onset
The RAD 140 half life measured in its one human trial was about 44.7 hours, the figure behind once-daily administration in women with breast cancer.
RAD 140 suppression and recovery: what the evidence shows
No published study has tested PCT for RAD 140, and a case report records suppressed testosterone normalising once supplements containing it were stopped.